Ross Lawrenson1, Chunhuan Lao2, Ian Campbell3, Vernon Harvey4, Sanjeewa Seneviratne5, Melissa Edwards3, Mark Elwood6, Nina Scott7, Jacquie Kidd8, Diana Sarfati9, Marion Kuper-Hommel7. 1. Medical Research Unit, The University of Waikato, Level 3 Hockin Building, Waikato Hospital, Hamilton, New Zealand. Ross.Lawrenson@waikatodhb.health.nz. 2. Medical Research Unit, The University of Waikato, Level 3 Hockin Building, Waikato Hospital, Hamilton, New Zealand. 3. School of Medicine, The University of Auckland, Auckland, New Zealand. 4. Auckland City Hospital, Auckland, New Zealand. 5. Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. 6. School of Population Health, The University of Auckland, Auckland, New Zealand. 7. Waikato District Health Board, Hamilton, New Zealand. 8. School of Nursing, The University of Auckland, Auckland, New Zealand. 9. Department of Public Health, The University of Otago, Wellington, New Zealand.
Abstract
PURPOSE: This study aims to look at the distribution of different subtypes of stage I-III breast cancer in Māori and Pacific versus non-Māori/Pacific women, and to examine cancer outcomes by ethnicity within these different subtypes. METHOD: This study included 9,015 women diagnosed with stage I-III breast cancer between June 2000 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, who had complete data on ER, PR and HER2 status. Five ER/PR/HER2 subtypes were defined. Kaplan-Meier method and Cox proportional hazards model were used to examine ethnic disparities in breast cancer-specific survival. RESULTS: Of the 9,015 women, 891 were Māori, 548 were Pacific and 7,576 others. Both Māori and Pacific women were less likely to have triple negative breast cancer compared to others (8.6, 8.9 vs. 13.0%). Pacific women were more than twice as likely to have ER-, PR- and HER2+ cancer than Māori and others (14.2 vs. 6.0%, 6.7%). After adjustment for age, year of diagnosis, stage, grade and treatment, the hazard ratios of breast cancer-specific mortality for Māori and Pacific women with ER+, PR+ and HER2- were 1.52 (95% CI 1.06-2.18) and 1.55 (95% CI 1.04-2.31) compared to others, respectively. Māori women with HER2+ cancer were twice more likely to die of their cancer than others. CONCLUSIONS: Outcomes for Māori and Pacific women could be improved by better treatment regimens especially for those with HER2+ breast cancer and for women with ER+, PR+ and HER2- breast cancer.
PURPOSE: This study aims to look at the distribution of different subtypes of stage I-III breast cancer in Māori and Pacific versus non-Māori/Pacific women, and to examine cancer outcomes by ethnicity within these different subtypes. METHOD: This study included 9,015 women diagnosed with stage I-III breast cancer between June 2000 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, who had complete data on ER, PR and HER2 status. Five ER/PR/HER2 subtypes were defined. Kaplan-Meier method and Cox proportional hazards model were used to examine ethnic disparities in breast cancer-specific survival. RESULTS: Of the 9,015 women, 891 were Māori, 548 were Pacific and 7,576 others. Both Māori and Pacific women were less likely to have triple negative breast cancer compared to others (8.6, 8.9 vs. 13.0%). Pacific women were more than twice as likely to have ER-, PR- and HER2+ cancer than Māori and others (14.2 vs. 6.0%, 6.7%). After adjustment for age, year of diagnosis, stage, grade and treatment, the hazard ratios of breast cancer-specific mortality for Māori and Pacific women with ER+, PR+ and HER2- were 1.52 (95% CI 1.06-2.18) and 1.55 (95% CI 1.04-2.31) compared to others, respectively. Māori women with HER2+ cancer were twice more likely to die of their cancer than others. CONCLUSIONS: Outcomes for Māori and Pacific women could be improved by better treatment regimens especially for those with HER2+ breast cancer and for women with ER+, PR+ and HER2- breast cancer.
Entities:
Keywords:
Breast cancer; Estrogen receptor; Ethnic disparities; Human epidermal growth factor receptor 2; Progesterone receptor; Subtypes
Authors: Chunhuan Lao; Marion Kuper-Hommel; Mark Elwood; Ian Campbell; Melissa Edwards; Ross Lawrenson Journal: Breast Cancer Date: 2020-10-12 Impact factor: 4.239
Authors: J Mark Elwood; Essa Tawfiq; Sandar TinTin; Roger J Marshall; Tung M Phung; Ian Campbell; Vernon Harvey; Ross Lawrenson Journal: BMC Cancer Date: 2018-09-17 Impact factor: 4.430
Authors: David Banham; David Roder; Marion Eckert; Natasha J Howard; Karla Canuto; Alex Brown Journal: BMC Health Serv Res Date: 2019-10-29 Impact factor: 2.655